ARS Pharmaceuticals (SPRY) Insider Management Buys 30,000 Shares

Insider Buying and Selling at ARS Pharmaceuticals, Inc.

Leadership at ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) stepped in to buy fresh stock on June 24, 2026, with several key figures acquiring identical blocks. Filings show that Phillip Schneider, Pratik Shah, Saqib Islam, Brent Saunders, Laura Shawver, and Peter Thompson each picked up 30,000 shares of the company on that day. Group transactions of this size often draw market notice, as leaders align their personal stakes with the direction of the enterprise.

Stock Trades Near Key Moving Average

Shares of ARS Pharmaceuticals trade around $8.54, sitting right near the 200-day moving average of $8.38. The stock has seen active movement over the past year, stretching from a 52-week low of $4.07 up to a high of $13.15. With a market cap of roughly $432.6 million, the company occupies a notable spot in the biotechnology space as it works on commercial products.

Recent Earnings And Financial Metrics

The San Diego-based biotech firm reported $116.9 million in revenue with a revenue growth rate of 1.142. The company posted a net margin of -1.84 and a return on equity of -2.10, while earnings per share stood at -2.18. Because the firm is not yet profitable on a net basis, it has no meaningful forward P/E ratio. The next earnings report is scheduled for November 10, 2026.

Analysts Set New Price Targets

Analyst updates have kept pace with the clinical and market developments at the firm. On June 25, 2026, Leerink Partners maintained an Outperform rating while adjusting its price target from $25.00 to $24.00. Later on August 13, 2026, Leerink Partners maintained its Outperform rating with a further target adjustment to $18.00. Across the broader analyst community, the consensus sits at a strong buy with a mean price target of $22.50 based on four analyst opinions, alongside a high target of $30.00 and a low of $15.00.

Inside The Business Of Severe Allergies

ARS Pharmaceuticals focuses on developing treatments for severe allergic reactions. Its lead product candidate is neffy, a needle-free intranasal delivery method for epinephrine designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Founded in 2015, the firm works to bring alternative delivery mechanisms to patients in the United States and abroad.

What to Watch at ARS Pharmaceuticals, Inc.

Market participants will look toward the upcoming earnings release on November 10, 2026, for further financial updates. Observers will also track future SEC filings to see if insiders continue adding to their holdings as the clinical pipeline evolves.